33 Results for "

PET imaging agent

" in MedChemExpress (MCE) Product Catalog:
Products (33)

33 Results for "PET imaging agent" in MCE Product Catalog:

Cat. No.: HY-P11837
Research Areas:  

Cancer

NECT-224 is a bifunctional chelator and a nectin-4 targeting peptide conjugate. NECT-224 can be used as a PET imaging agent when labeled with 64Cu or 68Ga .
loading...
    loading...
Cat. No.: HY-P12379
CAS No.: 1792977-97-9
Target:  

Guanylate Cyclase

Research Areas:  

Cancer

DOTA-MLN6907 is a guanylate cyclase C (GCC) binding agent. DOTA-MLN6907 competitively binds GCC receptors in vitro with an IC50 of approximately 4.6 nM. DOTA-MLN6907, after labeling with Ga-68, can specifically bind to GCC-expressing cancer cells for PET imaging. DOTA-MLN6907 can be used for PET imaging studies of GCC-expressing tumors such as colorectal cancer and for stratified assessment of GCC expression levels .
loading...
    loading...
Cat. No.: HY-181580
Target:  

FAP

Research Areas:  

Cancer

FAP Ligand 3 is a FAP ligand with a Ki value of 0.092 nM. FAP Ligand 3 acts as a tumor-retaining agent and serves as a FAP-targeted positron emission tomography (PET) tracer for tumor imaging. FAP Ligand 3 is applicable to studies related to glioma .
loading...
    loading...
Cat. No.: HY-P11718
CAS No.: 1000977-62-7
cFLFLF is a FPR-specific peptide. cFLFLF is sequentially conjugated with a bifunctional polyethylene glycol moiety (PEG, 3.4 kD) and a DOTA through a lysine (K) spacer and finally labeled with 64Cu-CuCl2 to form cFLFLFKPEG- 64Cu. cFLFLFKPEG- 64Cu is a neutrophil-specific PET imaging agent .
loading...
    loading...
Cat. No.: HY-P11613
Target:  

EGFR

Research Areas:  

Cancer

DOTA-WC8 is a HER2-targeting peptide probe with a KD of 61.20 nM. 68Ga-labeled DOTA-WC8 serves as a PET imaging agent for the specific identification of HER2-positive breast cancer. DOTA-WC8 is applicable to breast cancer-related research .
loading...
    loading...
Cat. No.: HY-186244
CAS No.: 50484-98-5
Target:  

5-HT Receptor

Research Areas:  

Neurological Disease

Methyl-2-bromo-LSD is a blood-brain barrier-penetrant serotonin 5-HT2 receptor ligand and PET imaging agent that binds 5-HT2 receptors with high affinity and achieves selective labeling of cortical regions. Methyl-2-bromo-LSD is useful for research on Alzheimer's disease, depression, schizophrenia, and anxiety disorders .
loading...
    loading...
Cat. No.: HY-W422109
CAS No.: 1345866-66-1
Target:  

Drug Derivative

Research Areas:  

Others

4-(6-Methyl-1,2,4,5-tetrazin-3-yl) benzoic acid is an asymmetric tetrazine derivative and a bioorthogonal reaction partner. 4-(6-Methyl-1,2,4,5-tetrazin-3-yl) benzoic acid can be conjugated with Bevacizumab (HY-P9906) via EDC/NHS activation while retaining the VEGF-binding affinity of the antibody, thus constructing a targeting agent for pretargeted immuno-PET/NIRF imaging .
loading...
    loading...
Cat. No.: HY-P11858
Research Areas:  

Cancer

DP1 peptide is a high-affinity ROR1-binding peptide with a Kd value of 74.9 nM. When labeled with 68Ga, DP1 peptide serves as a PET imaging agent, which features rapid tumor uptake, favorable target-to-nontarget ratios in various tumor models, and renal clearance, enabling non-invasive quantitative visualization of ROR1 expression. DP1 peptide can be used in research related to melanoma, hepatocellular carcinoma, colorectal cancer, and non-small cell lung cancer .
loading...
    loading...
Cat. No.: HY-181478
Target:  

HSP

Research Areas:  

Cancer

Hsp90-IN-45 is a Hsp90 inhibitor. Hsp90-IN-45 competitively binds to the ATP-binding site of purified Hsp90α with a Kd of 70 nM, blocks ATP hydrolysis, and disrupts Hsp90 client signaling. Hsp90-IN-45 inhibits ATPase activity of purified Hsp90α. Hsp90-IN-45 will be radiolabeled with 76/ 77Br for use as a radiotheragnostic agent for PET imaging and Meitner-Auger electron therapy. Hsp90-IN-45 can be used for the research of cancer .
loading...
    loading...
Cat. No.: HY-P11618
Target:  

Glycoprotein VI

Research Areas:  

Cancer

10P3Me is a Glypican-3 (GPC3)-targeting probe with a Ka of 93.8 nM for the human target. 10P3Me exhibits high binding affinity to GPC3, targets GPC3-positive cells, and serves as an agent for PET imaging. 10P3Me selectively accumulates in GPC3-positive tumor tissues, including subcutaneous xenograft models and orthotopic HepG2-LUC liver cancer models, to achieve precise localization of lesions .
loading...
    loading...
Cat. No.: HY-P12120
CAS No.: 499773-67-0
Synonyms: KCCYSL
Research Areas:  

Cancer

ErbB-2-binding peptide-2 (KCCYSL) is a peptide targeting ErbB-2/HER2, which specifically binds to the extracellular domain of HER2 and accumulates in HER2-expressing cancer cells. When radiolabeled, ErbB-2-binding peptide-2 serves as a SPECT/CT and PET imaging agent, enabling the visualization of HER2-expressing tumor xenografts. ErbB-2-binding peptide-2 is applicable to research related to ovarian cancer and breast cancer .
loading...
    loading...
Cat. No.: HY-P992340

Research Areas:  

Cancer

CTB006 is a monoclonal antibody targeting a humanized chimeric recombinant anti-DR5. CTB006 specifically binds to and activates DR5, thereby inducing tumor cell apoptosis, inhibiting tumor growth and reducing tumor drug resistance. 177Lu-radiolabeled CTB006 can deliver targeted radiotherapy to tumor cells; while 89Zr- or 177Lu-labeled CTB006 can serve as a PET/CT imaging agent for detecting DR5 expression levels in preclinical tumor models and screening cancers with DR5 overexpression. CTB006 can be applied to research related to gastrointestinal cancer, colorectal cancer and other solid tumors .
loading...
    loading...
Cat. No.: HY-181494
CAS No.: 3056070-96-0
Target:  

FAP

Research Areas:  

Cancer

FAPI-X5 is a fibroblast activation protein (FAP) inhibitor. FAPI-X5 binds to the FAP catalytic domain, forming hydrogen bonds with key active residues and engaging in π-π stacking to drive functional inhibition. FAPI-X5 exhibits albumin binding activity to prolong systemic circulation half-life. FAPI-X5 induces cytostatic effects on glioblastoma tumors, slowing tumor growth without regression. FAPI-X5, when labeled with 68Ga, acts as a PET tracer with rapid tumor uptake and high-contrast imaging in glioblastoma tumor-bearing mice. FAPI-X5, when labeled with 177Lu or 47Sc, functions as a targeted radionuclide agent with prolonged tumor retention. FAPI-X5 can be used for the research of glioblastoma .
loading...
    loading...